{
    "clinical_study": {
        "@rank": "57193", 
        "acronym": "VANGUARD", 
        "brief_summary": {
            "textblock": "The purpose of the VANGUARD study is to demonstrate the safety of Vagal Nerve Stimulation\n      for the treatment of congestive heart failure with reduced ejection fraction, and to report\n      secondary measures of efficacy."
        }, 
        "brief_title": "VAgal Nerve Stimulation: safeGUARDing Heart Failure Patients", 
        "condition": "Heart Failure With Reduced Ejection Fraction", 
        "condition_browse": {
            "mesh_term": "Heart Failure"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Left ventricular dysfunction of ischemic or idiopathic dilated cardiomyopathy\n             etiology, characterized by LVEF < 40%\n\n          2. Chronic heart failure with symptoms characterized by NYHA functional class II or III\n             at the time of enrollment despite optimal drug regimen\n\n          3. Optimal drug regimen as defined in the current European guidelines\n\n          4. Sinus rhythm, with spontaneous heart rate \u2265 60bpm at the time of enrollment\n\n          5. Signed and dated informed consent\n\n        Main Exclusion Criteria:\n\n          -  Patient implanted with or eligible to cardiac pacing as per current guideline\n\n          -  Risk for neck surgery in the electrode zone within a year after enrollment\n\n          -  Patient with right carotid artery stenosis\n\n          -  Symptomatic hypotension\n\n          -  History of peptic ulcer disease or upper gastrointestinal bleeding\n\n          -  Asthma, severe COPD, or severe restrictive lung disease\n\n          -  Advanced Diabetes Mellitus\n\n          -  Recent acute myocardial infarction, coronary artery surgery or revascularization (or\n             already planned)\n\n          -  Recent cerebro-vascular event\n\n          -  Significant valvulopathy\n\n          -  Advanced Renal failure\n\n          -  Previous heart transplant or current LVAD device therapy\n\n          -  Life expectancy < 1 year for non-cardiac cause\n\n          -  Patient included in another clinical study that could confound the results of this\n             study\n\n          -  Inability to understand the purpose of the study or to perform the procedures of the\n             study\n\n          -  Unavailability for scheduled follow-up\n\n          -  Age of less than 18 years or under guardianship\n\n          -  Pregnancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "April 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02113033", 
            "org_study_id": "NVNS01"
        }, 
        "intervention": {
            "description": "Vagal Nerve Stimulation synchronized with cardiac activity", 
            "intervention_name": "Equilia\u00ae  Vagal Nerve Stimulation", 
            "intervention_type": "Device", 
            "other_name": "Device used: Equilia\u00ae"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 11, 2014", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Adverse device effects will be sub-classified into device-related or procedure-related, when the adverse event has a generic cause independent from the device itself and occurs within 30 days of the implant procedure.", 
            "measure": "The primary outcome measure is the freedom from Serious Adverse Device Effects, defined as the number of patients without SADEs.", 
            "safety_issue": "Yes", 
            "time_frame": "6 Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02113033"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Sorin Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sorin Group", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}